Harald Renz is a co-founder of sterna biologicals and the company's chairman.
He is Professor of Laboratory Medicine at the Philipps University of Marburg, Germany, and is sub-specialised in Clinical Immunology and Allergology. He is Head of the Institute of Laboratory Medicine and Pathobiochemistry - Molecular Diagnostics of the University Hospital Gießen and Marburg GmbH.
His work on disease-related animal models has let to the development of mouse models for various disease-related phenotypes (including acute and chronic airway inflammation, airway remodeling, perinatal immune-development).
He has further developed the concept of neuro-immune interaction in bronchial asthma and atopic dermatitis and is currently involved in the translation of the hygiene hypothesis from epidemiology into mechanism of action. He has published more than 200 original articles in peer-reviewed international journals. He has contributed to 87 review articles and editorials and has edited 44 book chapters.
He is an active member in several national and international scientific societies including the American Academy of Allergy, Asthma & Immunology (AAAAI), European Academy of Allergy & Clinical Immunology (EAACI), European Respiratory Society (ERS) and is currently President of the German Society of Allergology and Clinical Immunology (DGAKI).
Holger Garn is a biologist with specific focus on immunobiology.
Since 2003 he has been the Head of Research at the Institute of Laboratory Medicine and Pathobiochemistry - Molecular Diagnostics of the Philipps University of Marburg, where he was appointed Associate Professor in 2015.
Holger is an acknowledged expert in the field of immune mechanisms of chronic inflammatory diseases. His scientific activities involve animal and human studies in this area with specific focus on novel concepts of therapy and prevention. He is well experienced in setting up and managing collaborative research projects with partners in academia and industry.
sterna biologicals has established high calibre scientific advisory boards with internationally renowned and globally most respected therapeutic area experts. Together with their help, sterna continues to swiftly advance the company`s non-clinical and clinical development programs. For further information, please contact us.